open the file
... hospitalization for worsening PAH, and to improve exercise ability. This approval was based on the results of the Ambition trial in which participants were started on combination therapy as initial treatment and demonstrated less clinical failure than those that were started on monotherapy of either ...
... hospitalization for worsening PAH, and to improve exercise ability. This approval was based on the results of the Ambition trial in which participants were started on combination therapy as initial treatment and demonstrated less clinical failure than those that were started on monotherapy of either ...
Detailed Advice - Scottish Medicines Consortium
... adults who are initially hospitalised due to ABSSSI, require intravenous antibiotics, but are eligible for early discharge as soon as their medical condition does not require further inpatient treatment. Evidence for efficacy comes from two key phase III double-blind, non-inferiority studies (DISCOV ...
... adults who are initially hospitalised due to ABSSSI, require intravenous antibiotics, but are eligible for early discharge as soon as their medical condition does not require further inpatient treatment. Evidence for efficacy comes from two key phase III double-blind, non-inferiority studies (DISCOV ...
Document
... use of endovascular stents. Approximately 1 million coronary stents are implanted in the US annually (~ 1.3 stents per patient) ...
... use of endovascular stents. Approximately 1 million coronary stents are implanted in the US annually (~ 1.3 stents per patient) ...
Medical Transcription Teachers - The SUM Program for Medical
... In 2001, ISMP published a list of problematic abbreviations, acronyms, and symbols that are inherently ambiguous or, when written by hand, potentially so. Two years later the Joint Commission on Accreditation of Healthcare Organizations (JCAHO or Joint Commission) launched a vigorous program to redu ...
... In 2001, ISMP published a list of problematic abbreviations, acronyms, and symbols that are inherently ambiguous or, when written by hand, potentially so. Two years later the Joint Commission on Accreditation of Healthcare Organizations (JCAHO or Joint Commission) launched a vigorous program to redu ...
The MABA approach: a new option to improve bronchodilator therapy Mario Cazzola
... numerous. MABAs offer an enhanced patent position and this is a crucial point for their commercial strategies. Another key advantage for companies consists in the fact that a single molecule that confers both therapeutic effects can avoid the approval of each component separately as well as in combi ...
... numerous. MABAs offer an enhanced patent position and this is a crucial point for their commercial strategies. Another key advantage for companies consists in the fact that a single molecule that confers both therapeutic effects can avoid the approval of each component separately as well as in combi ...
ceftin tablets and oral suspension
... CEFTIN for oral suspension is indicated for the treatment of pediatric patients aged 3 months to 12 years with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae (non-β-lactamase–producing strains only). Limitation ...
... CEFTIN for oral suspension is indicated for the treatment of pediatric patients aged 3 months to 12 years with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae (non-β-lactamase–producing strains only). Limitation ...
File - Healthy Living 1200
... Taking Drugs for the Wrong Reasons A drug can cause problems if it is taken for the wrong reason. A common example is using alcohol as a way of coping with unpleasant feelings, rather than drinking as part of a social or celebratory occasion. Taking Drugs Without Following Directions Taking drugs w ...
... Taking Drugs for the Wrong Reasons A drug can cause problems if it is taken for the wrong reason. A common example is using alcohol as a way of coping with unpleasant feelings, rather than drinking as part of a social or celebratory occasion. Taking Drugs Without Following Directions Taking drugs w ...
Safety of formoterol in asthma clinical trials: an update Malcolm R. Sears
... outcomes when following this latter recommendation [18–20]. The FDA has mandated, and pharmaceutical companies have initiated, large clinical trials to determine the safety of LABA by assessing outcomes in patients using LABA with ICS compared with the identical dose of ICS without LABA [21]. These ...
... outcomes when following this latter recommendation [18–20]. The FDA has mandated, and pharmaceutical companies have initiated, large clinical trials to determine the safety of LABA by assessing outcomes in patients using LABA with ICS compared with the identical dose of ICS without LABA [21]. These ...
O A RIGINAL RTICLE
... most parts of the world, producing about 250 million new infections, with a mortality estimate of about 1 million deaths each year; and approximately 85% of these deaths are among children, and most occur in Africa [74]. Half of the world's population is at risk from malaria, however, the disease is ...
... most parts of the world, producing about 250 million new infections, with a mortality estimate of about 1 million deaths each year; and approximately 85% of these deaths are among children, and most occur in Africa [74]. Half of the world's population is at risk from malaria, however, the disease is ...
Synergy
... The object is different but the experience obtained constitutes the basis of all medicine.” Our vision is for the CIC to be the premier veterinary research center for clinical trials in the United States. The best medical centers not only apply the most current information, they create it. To this e ...
... The object is different but the experience obtained constitutes the basis of all medicine.” Our vision is for the CIC to be the premier veterinary research center for clinical trials in the United States. The best medical centers not only apply the most current information, they create it. To this e ...
Non-opioid Analgesics - Surgical Critical Care. Net
... These agents are typically added to non-opioid analgesics when the patient’s pain does not respond to non-opioids alone. A common mistake is substituting one class of agent for the other. Both classes work well synergistically through their differing mechanisms of action. For this reason, opioids ar ...
... These agents are typically added to non-opioid analgesics when the patient’s pain does not respond to non-opioids alone. A common mistake is substituting one class of agent for the other. Both classes work well synergistically through their differing mechanisms of action. For this reason, opioids ar ...
Inappropriate drug use and mortality in community
... Methods The Three-City population-based study included 8701 participants 65 years from 1999 to 2001. Exposure to the risk of inappropriate drug dosage was defined as reported use of either a contraindicated drug or one requiring dose adjustment according to the individual baseline glomerular filtr ...
... Methods The Three-City population-based study included 8701 participants 65 years from 1999 to 2001. Exposure to the risk of inappropriate drug dosage was defined as reported use of either a contraindicated drug or one requiring dose adjustment according to the individual baseline glomerular filtr ...
Drug, substance that affects the function of living cells
... Distribution is the transport of a drug from the bloodstream to tissue sites where it will be effective, as well as to sites where the drug may be stored, metabolized, or eliminated from the body. Once a drug reaches its intended destination, the drug molecules move from blood through cellular barri ...
... Distribution is the transport of a drug from the bloodstream to tissue sites where it will be effective, as well as to sites where the drug may be stored, metabolized, or eliminated from the body. Once a drug reaches its intended destination, the drug molecules move from blood through cellular barri ...
Enhancement of dissolution rate of poorly water
... in a solid dosage form must undergo dissolution before it is available for absorption from the gastrointestinal tract1,2. The poor dissolution rates of water-insoluble drugs are still a substantial problem confronting the pharmaceutical industry3,4. The absorption rate of a poorly water-soluble drug ...
... in a solid dosage form must undergo dissolution before it is available for absorption from the gastrointestinal tract1,2. The poor dissolution rates of water-insoluble drugs are still a substantial problem confronting the pharmaceutical industry3,4. The absorption rate of a poorly water-soluble drug ...
Shiseido and Nihon Schering have concluded a joint business
... Overseas, the product has a history of over 30 years since Laboratoires Besins International, France, obtained approval in 1974 and has been approved or marketed in more than 100 countries to date. In Japan, Shiseido started the development as an ethical drug from 1995 and obtained a manufacturing a ...
... Overseas, the product has a history of over 30 years since Laboratoires Besins International, France, obtained approval in 1974 and has been approved or marketed in more than 100 countries to date. In Japan, Shiseido started the development as an ethical drug from 1995 and obtained a manufacturing a ...
TrendsRx® Alert
... LunestaTM (eszopiclone, Sepracor Inc.), formerly known as Estorra, was approved in December 2004 by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia.1,2 Lunesta falls in a class of medications known as sedative-hypnotics It is classified as a C-IV controlled substance; C-IV ...
... LunestaTM (eszopiclone, Sepracor Inc.), formerly known as Estorra, was approved in December 2004 by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia.1,2 Lunesta falls in a class of medications known as sedative-hypnotics It is classified as a C-IV controlled substance; C-IV ...
Acetazolamide: Considerations for Systemic Administration
... to reduce IOP with a systemic drug. Although most cases of neovascular glaucoma are refractory to long-term pharmacological treatment, a drug such as acetazolamide can be used as a temporizing measure while the physician plans a more definitive surgical approach. However, is acetazolamide appropriat ...
... to reduce IOP with a systemic drug. Although most cases of neovascular glaucoma are refractory to long-term pharmacological treatment, a drug such as acetazolamide can be used as a temporizing measure while the physician plans a more definitive surgical approach. However, is acetazolamide appropriat ...
Available
... ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient ...
... ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient ...
Niosome and Proniosome – Vesicular Structured Dosage Form for
... parts of the body relative to others. Targeted drug delivery seeks to concentrate the medication in the tissues of interest while reducing the relative concentration of the medication in the remaining tissues.1This improves efficacy of the while reducing side effects. Drug targeting is the delivery ...
... parts of the body relative to others. Targeted drug delivery seeks to concentrate the medication in the tissues of interest while reducing the relative concentration of the medication in the remaining tissues.1This improves efficacy of the while reducing side effects. Drug targeting is the delivery ...
Relation Extraction for Drug-Drug Interactions using Ensemble Learning
... for a case with exactly the same values for the features, i.e., it tries to find cases with exactly the same values for the mandatory features and matching as many optional features as possible. For the case retrieved in this step, a similarity between those and the original case is calculated by com ...
... for a case with exactly the same values for the features, i.e., it tries to find cases with exactly the same values for the mandatory features and matching as many optional features as possible. For the case retrieved in this step, a similarity between those and the original case is calculated by com ...
Amphetamines - EDAS Essential Drugs and Alcohol Services
... Amphetamine and methamphetamine are stimulant drugs. They increase breathing and heart rate, lessen appetite and make the pupils widen. Users tend to feel more alert, energetic, confident and cheerful and less bored or tired. With high doses people often experience a rapid flow of ideas and feel the ...
... Amphetamine and methamphetamine are stimulant drugs. They increase breathing and heart rate, lessen appetite and make the pupils widen. Users tend to feel more alert, energetic, confident and cheerful and less bored or tired. With high doses people often experience a rapid flow of ideas and feel the ...
investing in drug and alcohol treatment
... for those patients who are highly motivated to cease their opiate abuse. These include health care workers and those who pay large amounts of money for their treatment. Legally mandated naltrexone treatment may also be effective, but the evidence is equivocal. It has not been established whether the ...
... for those patients who are highly motivated to cease their opiate abuse. These include health care workers and those who pay large amounts of money for their treatment. Legally mandated naltrexone treatment may also be effective, but the evidence is equivocal. It has not been established whether the ...
Clinical Toolkit Benzodiazepines: Use and Taper
... the risks vs. benefit for the patient. Non-pharmacological measures and lower-risk therapeutic alternatives should be fully explored and the rationale for continued BDZ use, if applicable, should be well-documented in the patient’s chart. BDZ should ideally be prescribed by a single prescriber respo ...
... the risks vs. benefit for the patient. Non-pharmacological measures and lower-risk therapeutic alternatives should be fully explored and the rationale for continued BDZ use, if applicable, should be well-documented in the patient’s chart. BDZ should ideally be prescribed by a single prescriber respo ...
Withdrawing Drugs in the US Versus Other Countries
... withdrawn the drug, Europe continues to market it as a prescription and OTC drug. In the UK, it is sold in combinations with acetaminophen and caffeine as a cough and cold medication. Another drug that has been banned in the U.S. but is available outside the U.S is pergolide (Permax), a dopamine rec ...
... withdrawn the drug, Europe continues to market it as a prescription and OTC drug. In the UK, it is sold in combinations with acetaminophen and caffeine as a cough and cold medication. Another drug that has been banned in the U.S. but is available outside the U.S is pergolide (Permax), a dopamine rec ...
- Journal of Stroke and Cerebrovascular Diseases
... major differences between the ICTUS and the previous trials are displayed in Figure 3. The results of the ICTUS, thus, seem valid and almost doubles the available results of the effect of citicoline in AIS. Davalos et al29 have set a high standard of quality in the planning, conduction, and presenta ...
... major differences between the ICTUS and the previous trials are displayed in Figure 3. The results of the ICTUS, thus, seem valid and almost doubles the available results of the effect of citicoline in AIS. Davalos et al29 have set a high standard of quality in the planning, conduction, and presenta ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.